大行評級|中銀國際:上調中國鐵塔目標價至13.12港元 上調今明兩年盈測
中銀國際發表研究報告指,中國鐵塔去年下半年盈利增長10%,受惠於營業收入按年增長4.2%,略低於該行預期。該行指,鑑於營運商業務的韌性和兩翼業務的貢獻不斷增加,預計公司將繼續實現高質量增長,並持續提高股息。該行指,資本支出回報的提高必將提升公司的長期估值,對其今明兩年盈測上調介乎0.6%至1.5%,以反映經營開支上成本控制具紀律性,其目標價由12.54港元上調至13.12港元,重申其評級爲“買入”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.